Sepsis Diagnostics Market
Sepsis Diagnostics Market by Technology (Blood Culture, PCR, Immunoassay), Product (Culture, Assay, Instruments), Sample (Serum, blood), Test Type (Lab, POC), Pathogen (Bacterial), End User (Hospital, Pathology & Reference Labs) - Global Forecast to 2031
SEPSIS DIAGNOSTICS MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global sepsis diagnostics market is projected to grow from USD 0.83 billion in 2026 to USD 1.22 billion by 2031, at a CAGR of 7.9% during the forecast period. The market was valued at USD 0.78 billion in 2025. The global sepsis diagnostics market is expected to grow steadily through 2031, driven by the high incidence of sepsis and bloodstream infections, rising ICU admissions, growing adoption of rapid molecular and syndromic diagnostics, increased focus on antimicrobial stewardship, and expanding use of biomarker-based testing. Sepsis diagnostics are critical for early detection, pathogen identification, antimicrobial resistance assessment, risk stratification, and clinical decision support in emergency departments, ICUs, hospitals, and reference laboratories. The market encompasses blood culture media, assays and reagent kits, instruments, software, blood culture/microbiology testing, immunoassays, molecular diagnostics, mass spectrometry, clinical chemistry, blood gas analysis, and point-of-care testing solutions. Increasing demand for faster turnaround times, automated laboratory workflows, rapid pathogen detection, and AI-enabled sepsis decision support is expected to accelerate market expansion globally.
KEY TAKEAWAYS
-
MARKET SNAPSHOT:
Base Year Market Size (2025): USD 0.78 Billion
Current Market Size (2026): USD 0.83 Billion
Forecast Market Size (2031): USD 1.22 Billion
CAGR (2026–2031): 7.9% -
SEGMENT LEADERSHIP:
Regional Leader: North America accounted for the largest market share of 43.2% in 2025.
Product Leader: Assays & kits & reagents segment had the largest share of 40.7% in 2025.
End User Leader: Hospital & specialty clinics dominated the sepsis diagnostics market with a share of 62.7% in 2025. -
MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
bioMérieux SA, Becton, Dickinson and Company, Danaher Corporation, F. Hoffmann-La Roche AG, and Thermo Fisher Scientific Inc. were identified as some of the star players in the global sepsis diagnostics market, given their strong market share, broad infectious disease diagnostics portfolios, automated microbiology platforms, molecular testing capabilities, and established hospital laboratory presence.
Accelerate Diagnostics, Immunexpress, and QuidelOrtho have distinguished themselves among emerging and niche players by focusing on rapid pathogen detection, antimicrobial susceptibility testing, host-response biomarkers, molecular diagnostics, and decentralized sepsis testing solutions, underscoring their potential as future market leaders.
The global sepsis diagnostics market is expanding steadily, driven by the rising burden of sepsis and bloodstream infections, and by increasing adoption of automated blood culture systems, rapid molecular diagnostics, syndromic panels, immunoassays, and biomarker-based testing. Growing antimicrobial stewardship initiatives, rising demand for ICU testing, and the need for faster pathogen identification and antimicrobial resistance detection are accelerating the adoption of advanced sepsis diagnostic solutions across hospitals, specialty clinics, and reference laboratories.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
The sepsis diagnostics market is undergoing significant transformation, driven by rising rates of sepsis and bloodstream infections, increasing ICU admissions, and the growing need for faster clinical decision-making in emergency and critical care settings. Traditional culture-based workflows remain important, but the market is increasingly shifting toward rapid molecular diagnostics, syndromic testing panels, automated blood culture systems, antimicrobial susceptibility testing, and biomarker-based sepsis assessment. A growing focus on antimicrobial stewardship is accelerating demand for diagnostics that enable faster pathogen identification, resistance marker detection, and appropriate antibiotic selection. In parallel, AI-enabled sepsis diagnosis, clinical decision support, host-response biomarkers, point-of-care testing, and decentralized diagnostic models are disrupting conventional hospital laboratory workflows. These technologies are helping reduce diagnostic turnaround time, improve patient stratification, support early intervention, and optimize antimicrobial therapy. However, high costs of advanced molecular platforms, limited reimbursement for novel diagnostics, the clinical complexity of sepsis presentations, workflow integration challenges, and a shortage of trained laboratory personnel remain key barriers. As hospitals, reference laboratories, and diagnostic companies increasingly prioritize rapid, automated, and data-driven sepsis testing, the market is expected to evolve toward integrated diagnostic workflows that combine microbiology, molecular testing, biomarkers, automation, and clinical decision support.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
High incidence of sepsis and bloodstream infections
-
Growing adoption of rapid molecular and syndromic diagnostics
Level
-
High cost of advanced molecular diagnostic platforms0
-
Limited reimbursement for novel sepsis diagnostic technologies
Level
-
AI-enabled sepsis diagnosis and clinical decision support companion diagnostics
-
Development of next-generation host-response biomarkers
Level
-
Clinical complexity and heterogeneous presentation of sepsis
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: High incidence of sepsis and bloodstream infections
The high global burden of sepsis and bloodstream infections is a major driver of the sepsis diagnostics market. Sepsis requires rapid diagnosis and timely treatment because delays in pathogen identification and antimicrobial therapy can significantly worsen patient outcomes. Rising ICU admissions, hospital-acquired infections, antimicrobial-resistant infections, and bloodstream infection cases are increasing demand for blood culture systems, molecular diagnostics, immunoassays, and biomarker-based tests. Hospitals and laboratories are therefore investing in faster, more reliable diagnostic solutions to support early detection, pathogen identification, and treatment decisions.
Restraint: Limited reimbursement for novel diagnostic technologies
Limited or inconsistent reimbursement for novel sepsis diagnostic technologies can hinder broader market adoption. Although rapid molecular and biomarker-based tests offer clinical benefits, hospitals may struggle to justify their routine use when reimbursement coverage is unclear or insufficient. This is especially true for high-cost molecular panels, AI-enabled decision support tools, and emerging host-response biomarker tests.
Opportunity: AI-enabled sepsis diagnosis and clinical decision support
AI-enabled sepsis diagnosis and clinical decision support present a major market opportunity. AI tools can integrate laboratory results, patient vitals, electronic health records, microbiology data, and clinical risk indicators to support early sepsis detection and risk prediction. Integrating AI with diagnostic platforms can improve patient stratification, reduce missed or delayed diagnoses, and support timely intervention in emergency departments and ICUs.
Challenge: Clinical complexity and heterogeneous presentation of sepsis
Sepsis is clinically complex and often presents with heterogeneous symptoms that overlap with other inflammatory or infectious conditions. This makes diagnosis difficult, especially in the early stages. Variability in patient immune responses, pathogen types, comorbidities, and disease progression can affect how test results are interpreted. As a result, diagnostic companies must develop solutions that improve accuracy, clinical relevance, and usability across diverse patient populations.
SEPSIS DIAGNOSTICS MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Provides integrated sepsis diagnostics solutions across automated blood culture, rapid syndromic molecular testing, microbial identification, and antimicrobial susceptibility testing through platforms used in hospital microbiology laboratories | Enables faster bloodstream infection detection, rapid pathogen identification, improved antimicrobial selection, and stronger antimicrobial stewardship support |
 |
Supports sepsis and bloodstream infection diagnostics through blood culture systems, specimen collection products, microbiology automation, and antimicrobial susceptibility testing solutions used across hospitals and reference laboratories | Improves laboratory workflow efficiency, supports high-volume microbiology testing, reduces turnaround time, and helps clinicians optimize antibiotic therapy |
 |
Through its diagnostics businesses, provides molecular diagnostics, clinical chemistry, immunoassay, and laboratory automation solutions that support infectious disease testing and sepsis-related clinical decision-making | Supports rapid pathogen detection, biomarker-based assessment, automated laboratory workflows, and improved diagnosis of suspected sepsis cases |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The global sepsis diagnostics market is a complex ecosystem involving in vitro diagnostic companies, blood culture and microbiology platform providers, molecular diagnostics firms, immunoassay and biomarker testing companies, hospital laboratories, reference labs, emergency departments, ICUs, antimicrobial stewardship teams, research institutes, and regulatory bodies. These players collaborate to enable early sepsis detection, bloodstream infection diagnosis, pathogen identification, antimicrobial resistance assessment, and clinical decision support. Vendors supply blood culture media, assays, reagent kits, instruments, software, automated systems, microbial identification platforms, antimicrobial susceptibility testing devices, molecular diagnostic panels, immunoassays, mass spectrometry platforms, clinical chemistry analyzers, blood gas analyzers, and point-of-care solutions. Hospitals and clinics use these in emergency departments, ICUs, critical care units, infectious disease wards, and inpatient settings for rapid diagnosis and treatment. Pathology and reference labs perform high-volume and confirmatory testing, outsource microbiology, biomarker, and molecular diagnostics. Research labs, academic institutes, and CROs drive biomarker discovery, assay validation, risk stratification research, and clinical trials. Regulatory agencies such as the US FDA, European IVDR bodies, MHRA, PMDA, Health Canada, and NMPA influence via approvals, standards, and diagnostic labeling. The ecosystem is driven by the high burden of sepsis and bloodstream infections, rising ICU admissions, focus on antimicrobial stewardship, adoption of rapid molecular and syndromic diagnostics, biomarker-based testing expansion, and AI-enabled clinical decision support integration.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Global Sepsis Diagnostics Market, by Product
Assays & reagent kits are expected to account for the largest share of the sepsis diagnostics market due to their recurring use across blood culture testing, immunoassays, molecular diagnostics, antimicrobial susceptibility testing, biomarker-based testing, and syndromic panels. These consumables are required for every patient test, unlike instruments, which are capital purchases with longer replacement cycles. Blood culture media continues to hold an important share due to its role in conventional bloodstream infection detection, while instruments are supported by the increasing installation of automated blood culture systems, molecular platforms, mass spectrometry systems, clinical chemistry analyzers, and blood gas analyzers. Software is gaining traction as laboratory informatics, antimicrobial stewardship tools, AI-enabled decision support, and workflow automation become more integrated.
Global Sepsis Diagnostics Market, by Technology
Blood culture/microbiology testing held the largest share of the sepsis diagnostics market in 2025, due to its established role as the conventional standard for detecting bloodstream infections and supporting antimicrobial susceptibility testing. Blood culture remains central to sepsis diagnosis because it enables pathogen recovery, identification, and guidance for therapy. Molecular diagnostics is expected to grow faster over the forecast period, supported by rising adoption of PCR/RT-PCR, multiplex PCR panels, microarrays, FISH/PNA-FISH, DNA sequencing, NGS, LAMP, and TMA-based methods for rapid detection of pathogens and resistance markers. Immunoassays, mass spectrometry, flow cytometry, and clinical chemistry and blood gas analysis also play important roles in biomarker assessment, organism identification, immune profiling, lactate monitoring, and critical care decision-making.
Global Sepsis Diagnostics Market, by Pathogen Type
In 2025, bacterial sepsis dominated the sepsis diagnostics market due to the high burden of bacterial bloodstream infections, hospital-acquired infections, ICU-related infections, and antimicrobial-resistant bacterial pathogens. Within bacterial sepsis, gram-negative and gram-positive sepsis are key subsegments due to their clinical severity and importance in antimicrobial therapy decisions. Fungal sepsis is gaining attention due to rising cases among immunocompromised patients, oncology patients, transplant recipients, and critically ill ICU patients. Other pathogen types, including parasitic and polymicrobial sepsis, account for a smaller but clinically important share, particularly in complex and region-specific infection settings.
Global Sepsis Diagnostics Market, by Test Type
Laboratory tests are expected to account for the largest share of the sepsis diagnostics market, driven by the central role of hospital laboratories, microbiology departments, and reference laboratories in blood culture testing, molecular diagnostics, immunoassays, antimicrobial susceptibility testing, mass spectrometry, and clinical chemistry testing. Laboratory-based testing remains essential for confirmatory diagnosis, organism identification, resistance profiling, and treatment guidance. Point-of-care tests are expected to grow faster due to increasing demand for rapid sepsis screening, emergency department testing, ICU-based decision support, decentralized biomarker testing, and faster clinical decision-making near the patient.
Global Sepsis Diagnostics Market, by Sample Type
In 2025, whole blood is expected to account for the largest share of the sepsis diagnostics market, by sample type, supported by its established use in blood culture testing, bloodstream infection diagnosis, molecular pathogen detection, and sepsis-related microbiology workflows. Whole blood remains central to sepsis diagnostics because pathogen detection, culture-based diagnosis, and molecular testing often rely on blood samples from suspected sepsis patients. Serum-based testing also holds an important share due to its use in immunoassays, inflammatory biomarker testing, host-response assessment, and clinical chemistry-based evaluation of sepsis severity and patient status.
Global Sepsis Diagnostics Market, by Plexity
Singleplex testing is expected to account for a major share of the sepsis diagnostics market due to its widespread use in routine biomarker assays, targeted pathogen testing, conventional diagnostic workflows, and cost-sensitive laboratory settings. However, multiplex testing is expected to grow faster over the forecast period, supported by the rising adoption of syndromic panels and molecular platforms that can detect multiple pathogens, resistance genes, and infection markers in a single test. Multiplex testing is increasingly important in sepsis diagnostics because faster identification of causative pathogens and resistance markers can support targeted antimicrobial therapy and antimicrobial stewardship.
Global Sepsis Diagnostics Market, by End User
In 2025, hospitals and specialty clinics are expected to account for the largest share of the sepsis diagnostics market, driven by the high volume of suspected sepsis cases managed in emergency departments, ICUs, inpatient wards, and critical care units. Hospitals are the primary users of blood culture systems, rapid molecular tests, immunoassays, clinical chemistry analyzers, blood gas analyzers, and antimicrobial stewardship-linked diagnostic workflows. Pathology and reference laboratories also hold a significant share by supporting high-volume infectious disease testing, confirmatory diagnostics, outsourced microbiology, molecular testing, and biomarker analysis. Research laboratories, academic institutes, and CROs contribute through biomarker discovery, diagnostic validation, clinical studies, and sepsis-related translational research.
REGION
Asia Pacific to be fastest-growing region in market during forecast period
During the forecast period, Asia Pacific is expected to be the fastest-growing region in the sepsis diagnostics market, driven by the rising burden of sepsis and bloodstream infections, expanding hospital and ICU infrastructure, rising healthcare expenditure, and growing adoption of rapid molecular diagnostics, automated blood culture systems, immunoassays, and biomarker-based testing across China, Japan, India, South Korea, Australia, and Southeast Asia. Japan and South Korea are advancing through strong hospital laboratory infrastructure, higher adoption of automated microbiology and molecular testing platforms, and a growing focus on antimicrobial stewardship. China and India are experiencing rapid expansion of diagnostic capacity, critical care services, and microbiology testing infrastructure, supported by improving healthcare access and increasing awareness of early sepsis diagnosis. Growing demand for faster pathogen identification, resistance marker detection, and improved clinical decision-making is expected to further support regional growth. However, adoption is likely to remain uneven across the region due to differences in healthcare infrastructure, reimbursement maturity, laboratory capacity, the affordability of advanced diagnostics, and access to trained personnel.
SEPSIS DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX
bioMérieux SA is a leading player in the sepsis diagnostics market, supported by a broad portfolio spanning automated blood culture systems, microbiology testing, microbial identification, antimicrobial susceptibility testing, immunoassays, and syndromic molecular diagnostics. Becton, Dickinson and Company is also a major strategic player, driven by its strong installed base in blood culture, specimen collection, microbiology automation, and antimicrobial susceptibility testing workflows across hospital and reference laboratories. Danaher Corporation, through its diagnostics businesses such as Cepheid and Beckman Coulter, holds a strong position through rapid molecular diagnostics, clinical chemistry, immunoassays, and laboratory automation platforms used in infectious disease and sepsis-related testing. F. Hoffmann-La Roche AG remains an important player due to its molecular diagnostics, immunoassay, and clinical chemistry testing capabilities, while Thermo Fisher Scientific Inc. is strongly positioned through its biomarker-based testing, molecular diagnostics, microbiology, and laboratory solutions. Overall, the market is led by integrated diagnostics companies with strong hospital laboratory penetration, broad infectious disease portfolios, automated testing platforms, and the ability to support early sepsis diagnosis, pathogen identification, antimicrobial stewardship, and clinical decision-making. Emerging and specialized players such as Accelerate Diagnostics, Immunexpress, and QuidelOrtho are gaining traction through rapid pathogen detection, host-response biomarkers, mass spectrometry, antimicrobial susceptibility testing, and decentralized sepsis testing solutions.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Biomérieux (France)
- Becton Dickinson And Company (US)
- Danaher Corporation (US)
- Thermo Fisher Scientific Inc. (US)
- F. Hoffmann-La Roche Ag (Switzerland)
- Diasorin S.P.A (US)
- Bruker Corporation (US)
- Abbott Laboratories (US)
- Sysmex Corporation (Japan)
- Siemens Healthineers (Germany)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 0.78 Billion |
| Market Size in 2026 (Value) | USD 0.83 Billion |
| Market Forecast in 2031 (Value) | USD 1.22 Billion |
| Growth Rate | CAGR of 7.9% from 2026-2031 |
| Years Considered | 2024–2031 |
| Base Year | 2025 |
| Forecast Period | 2026–2031 |
| Units Considered | Value (USD Million/Billion) |
| Report Coverage | Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East, Africa |
WHAT IS IN IT FOR YOU: SEPSIS DIAGNOSTICS MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Evaluate competitive positioning of key players in the sepsis diagnostics market | Benchmarked leading companies across blood culture systems, assays & reagent kits, automated microbiology platforms, molecular diagnostics, immunoassays, biomarker-based tests, antimicrobial susceptibility testing, mass spectrometry platforms, clinical chemistry & blood gas analyzers, and sepsis-focused software solutions based on technology coverage, product portfolio, installed base, regulatory approvals, geographic reach, hospital laboratory presence, and end-user focus | Identifies competitive gaps, partnership opportunities, product differentiation strategies, and right-to-win areas across rapid pathogen detection, antimicrobial stewardship support, automated diagnostics, and sepsis biomarker testing |
| Assess high-growth technologies and segment opportunities in sepsis diagnostics | Evaluated growth potential across rapid molecular diagnostics, syndromic multiplex panels, automated blood culture systems, automated ID/AST platforms, host-response biomarkers, point-of-care sepsis testing, AI-enabled clinical decision support, mass spectrometry, and decentralized testing workflows, including differences in adoption across hospitals, specialty clinics, pathology/reference laboratories, research institutes, and CROs | Supports investment prioritization, product development, regional expansion, commercialization planning, and technology roadmap decisions, especially around rapid molecular testing, antimicrobial stewardship, biomarker-based diagnosis, and AI-enabled sepsis risk prediction |
RECENT DEVELOPMENTS
- April 2026 : bioMérieux published a first-of-its-kind, multi-country health economic analysis showing that early implementation of rapid diagnostics for bloodstream infections can significantly reduce progression to sepsis, improve patient outcomes, and lower healthcare costs. The findings reinforce the growing clinical and economic value of rapid microbiology and antimicrobial stewardship solutions for sepsis management.
- February 2026 : Immunexpress presented new clinical evidence at the Society of Critical Care Medicine (SCCM) Critical Care Congress indicating that SeptiCyte® RAPID exhibited high concordance with cases of sepsis confirmed by physicians, including both blood culture-positive and culture-negative patients. These findings further substantiate the utility of host-response diagnostics for the early detection of sepsis.
- January 2025 : The US FDA granted marketing authorization to Inflammatix's TriVerity Test System, the first host-response molecular diagnostic designed to rapidly differentiate between bacterial and viral infections and to assess illness severity in patients with suspected sepsis. The approval marks a major advancement in AI-enabled precision diagnostics for emergency and critical care settings.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
This study involved four major activities to estimate the current size of the sepsis diagnostics market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Following this, data triangulation was used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study of the global sepsis diagnostics market. The secondary sources used in this study include publications from government and public health organizations such as the World Health Organization (WHO), Centers for Disease Control and Prevention (CDC), National Institutes of Health (NIH), National Center for Biotechnology Information (NCBI), Food and Drug Administration (FDA), European Medicines Agency (EMA), European Centre for Disease Prevention and Control (ECDC), and other regional health authorities. Secondary sources also included corporate and regulatory filings such as annual reports, SEC filings, investor presentations, and financial statements; company websites; product brochures and catalogs; press releases; peer-reviewed journals; clinical guidelines; sepsis-related publications; and infectious disease databases, among others.
These sources provided key information on major players, product portfolios, global product revenues, market classification, sepsis diagnostics technologies, product launches, regulatory approvals, clinical adoption trends, antimicrobial stewardship initiatives, and regional and country-level market developments. Secondary data were collected and analyzed to estimate the size of the global sepsis diagnostics market, and the findings were validated through primary research.
Primary Research
In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, product managers, laboratory directors, infectious disease specialists, microbiologists, pathologists, hospital procurement professionals, consultants, and other stakeholders to obtain and verify critical qualitative and quantitative information and to assess market prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative information. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the sepsis diagnostics market was estimated using multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market, including product, technology, method, pathogen type, test type, sample type, complexity, clinical utility/management pathway, end user, and region.
The market size estimate included revenues from blood culture media, assays and reagent kits, instruments, and software used in sepsis diagnostics. It also included technologies such as blood culture/microbiology testing, immunoassays, molecular diagnostics, flow cytometry, mass spectrometry, and clinical chemistry and blood gas analysis. Company revenues, product mapping, installed base, test volumes, average selling prices, adoption rates, disease burden, hospital testing patterns, and regional laboratory infrastructure were analyzed to estimate the market size.
Data Triangulation
After estimating the overall market size through the market size estimation process, the total market was divided into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved analyzing various factors and trends from both the demand and supply sides.
On the supply side, company revenues, product portfolios, installed base, product launches, regulatory approvals, geographic presence, and diagnostic platform adoption were analyzed. On the demand side, sepsis incidence, bloodstream infection burden, hospital admissions, ICU testing volumes, laboratory test utilization, antimicrobial stewardship requirements, and adoption of rapid molecular and biomarker-based diagnostics were considered. The final estimates were validated through primary interviews and cross-checked against secondary research.
Market Definition
Sepsis diagnostics refers to in vitro diagnostic products, platforms, and testing solutions used for the early detection, diagnosis, pathogen identification, risk stratification, antimicrobial stewardship support, and prognosis/outcome prediction of sepsis and bloodstream infections. These diagnostics help clinicians identify infection, determine the causative pathogen, assess disease severity, support antimicrobial treatment decisions, and monitor patient condition in emergency departments, ICUs, hospitals, specialty clinics, and diagnostic laboratories. The market includes blood culture media, assays and reagent kits, instruments, and software used across technologies such as blood culture/microbiology testing, immunoassays, molecular diagnostics, flow cytometry, mass spectrometry, and clinical chemistry and blood gas analysis. It also includes laboratory and point-of-care tests used for bacterial, fungal, parasitic, and polymicrobial sepsis, as well as other sepsis-related diagnostic applications.
Key Stakeholders
- Manufacturers and distributors of sepsis diagnostics products
- In vitro diagnostic (IVD) companies
- Blood culture and microbiology testing companies
- Molecular diagnostics companies
- Immunoassay and biomarker testing companies
- Mass spectrometry and microbial identification platform providers
- Clinical chemistry and blood gas analyzer manufacturers
- Point-of-care diagnostics companies
- Hospital laboratories
- Pathology and reference laboratories
- Hospitals and specialty clinics
- Emergency departments and intensive care units
- Infectious disease specialists, microbiologists, and pathologists
- Research laboratories and academic institutes
- Clinical research organizations (CROs)
- Contract research and diagnostic service providers
- Regulatory authorities and government health agencies
- Public health organizations
- Group purchasing organizations and hospital procurement teams
- Diagnostics suppliers and raw material providers
- Market research and consulting firms
- Venture capitalists and investors
Report Objectives
- To define, describe, segment, and forecast the global sepsis diagnostics market, by product, technology, method, pathogen type, test type, sample type, plexity, clinical utility/management pathway, end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall sepsis diagnostics market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the market segments with respect to six regions: North America(US and Canada), Europe (Germany, France, the UK, Switzerland, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, and the Rest of Latin America), the Middle East [GCC and the Rest of Middle East], and Africa
- To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
- To analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, collaborations, expansions, and other developments
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
Available customizations:
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for the report:
Geographical Analysis
- Further breakdown of the Rest of Europe Sepsis Diagnostics market, by country
- Further breakdown of the Rest of Asia Pacific Sepsis Diagnostics market, by country
Company Information
- Detailed analysis and profiling of additional market players (up to five)
Segment Analysis
- Cross-segment analysis
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Sepsis Diagnostics Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free CustomisationTESTIMONIALS
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Companywww.sfihealth.com/
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Companywww.qualicaps.com/
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnosticsimaging.bracco.com/us-en
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.www.3m.com/3M/en_US/health-information-systems-us
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
- Italy Sepsis Diagnostics Market
- Spain Sepsis Diagnostics Market
- Japan Sepsis Diagnostics Market
- China Sepsis Diagnostics Market
- India Sepsis Diagnostics Market
- Australia Sepsis Diagnostics Market
- South Korea Sepsis Diagnostics Market
- Brazil Sepsis Diagnostics Market
- Mexico Sepsis Diagnostics Market
- US Sepsis Diagnostics Market
- Canada Sepsis Diagnostics Market
- Germany Sepsis Diagnostics Market
- UK Sepsis Diagnostics Market
- France Sepsis Diagnostics Market
Growth opportunities and latent adjacency in Sepsis Diagnostics Market
catherine
May, 2020
Have you not heard of T2 Biosystems rapid diagnostics direct from blood? Much faster than blood cultures, which is vital considering how quickly sepsis kills. FDA and CMS labeled it "breakthrough technology" and CMS subsidizes the test at 65, $97..
Barbara
Mar, 2022
What are the after-effects of the COVID19 on the Global Sepsis Diagnostics Industry?.
Susan
Mar, 2022
What are the upcoming trends in the Global Sepsis Diagnostics Industry?.